QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) An erratum has been published All Versions of this Article: dmd.104.000059v1 32/9/1023    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Liu, D. Q. Articles by Hop, C. E.C.A. Search for Related Content PubMed PubMed Citation Articles by Liu, D. Q. Articles by Hop, C. E.C.A.

IN VITRO METABOLISM OF MK-0767 [(±)-5-[(2,4-DIOXOTHIAZOLIDIN-5-YL)METHYL]-2-METHOXY-N-[[(4-TRIFLUOROMETHYL)-PHENYL] METHYL]BENZAMIDE], A PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR / AGONIST. II. IDENTIFICATION OF METABOLITES BY LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY

Departments of Drug Metabolism (D.Q.L., B.V.K., G.A.D., S.H.V., C.E.C.A.H.) and Process Research (R.R.S.), Merck Research Laboratories, Rahway, New Jersey

The in vitro metabolism of MK-0767 [(±)-5-[(2,4-dioxothiazolidin-5-yl) methyl]-2-methoxy-N-[[(4-trifluoromethyl)-phenyl] methyl]benzamide], a novel 2,4-thiazolidinedione (TZD)-containing peroxisome proliferator-activated receptor / agonist, was studied in rat, dog, monkey, and human liver microsomes and hepatocytes, as well as in recombinant human CYP3A4-containing microsomes. Twenty-two metabolites (some at trace levels) were detected by liquid chromatography-tandem mass spectrometry analysis. All appeared to be phase I metabolites except for a glucuronide conjugate of a hydroxylated metabolite that was detected at trace levels. A constant neutral loss scan experiment performed on a triple quadrupole mass spectrometer proved to be very useful for resolving the metabolites from endogenous compounds. It was observed that the initial site of metabolism of MK-0767 was at the TZD ring leading to two major metabolites, namely the 5-hydroxy-TZD metabolite (M24) and the mercapto metabolite (M22). The latter was formed via the cleavage of the TZD ring with the elimination of the carbonyl adjacent to the sulfur atom. The structure of M24 was established by accurate mass measurements and NMR analysis. This hydroxy-TZD metabolite might represent an important precursor for a group of metabolites formed by TZD ring opening and subsequent loss of the sulfur moiety. The mercapto metabolite, on the other hand, is probably the key precursor for the TZD ring-opened metabolites with retention of the sulfur, even though the detailed mechanism of the ring scission remains to be characterized. From these studies, it was concluded that the TZD ring was the major site of metabolism of MK-0767. All the metabolites produced in vitro from human preparations were detected in the corresponding preparations from the nonclinical species.

This article has been cited by other articles:

				C. J. Kochansky, R. K. Rippley, K. X. Yan, H. Song, M. A. Wallace, D. Dean, A. N. Jones, K. Lasseter, J. Schwartz, S. H. Vincent, et al. Drug Metab. Dispos., September 1, 2006; 34(9): 1457 - 1461. [Abstract] [Full Text] [PDF]

				V. B. G. Reddy, G. A. Doss, M. Creighton, C. J. Kochansky, S. H. Vincent, R. B. Franklin, and B. V. Karanam Drug Metab. Dispos., October 1, 2004; 32(10): 1154 - 1161. [Abstract] [Full Text] [PDF]

				B. V. Karanam, C. E.C.A. Hop, D. Q. Liu, M. Wallace, D. Dean, H. Satoh, M. Komuro, K. Awano, and S. H. Vincent Drug Metab. Dispos., September 1, 2004; 32(9): 1015 - 1022. [Abstract] [Full Text] [PDF]